Severity of coronary artery disease is associated with non-alcoholic fatty liver dis-ease: A single-blinded prospective mono-center study

PLoS One

Sebastian Maier¹  Joerg Bojunga¹  Fabian Schoelzel¹  Mireen Friedrich-Rust¹  Florian Seeger²  Stephan Fichtlscherer²  Eva Herrmann³  Julia Rey³  Stefan Zeuzem⁴ 

[1] Department of Internal Medicine 1, Hospital of the Goethe University, Frankfurt, Germany;Department of Internal Medicine 3, Hospital of the Goethe University, Frankfurt, Germany;Department of Medicine, Institute of Biostatistics and Mathematical Modelling, Goethe University Frankfurt, Frankfurt, Germany;German Center for Cardiovascular Research, DZHK, partner site Frankfurt Rhine-Main, Berlin, Germany

关键词: Coronary heart disease;    Fibrosis;    Steatosis;    Fatty liver;    Liver fibrosis;    Angiography;    Metabolic disorders;    Ultrasound imaging;   

DOI  :  10.1371/journal.pone.0186720

学科分类：医学（综合）

来源: Public Library of Science

【 摘 要 】

Background and aims Liver steatosis has shown to be associated with coronary artery disease (CAD). The aim of our study was to evaluate the association between the presence and severity of CAD and Non-alcoholic fatty liver disease (NAFLD) assessed by transient elastography (TE) and controlled attenuation parameter (CAP). Methods 576 Patients undergoing coronary angiography were enrolled in this prospective study, receiving at least 10 TE and CAP measurements using the FibroScan® M-probe. Clinically relevant CAD (CAD 3) was defined as stenosis with ≥75% reduction of the luminal diameter. NAFLD was determined by CAP ≥234 dB/m. NAFLD with advanced fibrosiswas determined by TE-values ≥7.9kPa in the presence of NAFLD and absence of congestive or right-sided heart failure. Rates and 95% confidence intervals are shown. Results 505 patients were available for analysis of NAFLD. However, only 392 patients were available for analysis of NAFLD with advanced fibrosis, since 24 patients had to be excluded due to non valid TE-measurements and 89 patients due to congestive or right-sided heart failure or suspected concomitant liver disease, respectively. 70.5% (66.3%-74.4%) of patients had CAD 3, 71.5% (67.3%-75.4%) were diagnosed with NAFLD, and 11.2% (8.3%-14.8%) with NAFLD with advanced fibrosis. Patients with CAD 3 had higher median CAP-values (273±61 vs. 260±66 dB/m; p = 0.038) and higher degrees of steatosis as compared to patients without CAD 3. While NAFLD was significantly more often diagnosed in patients with CAD 3 (75.0% vs. 63.1%, p = 0.0068), no significant difference was found for NAFLD with advanced fibrosis (10.7% vs. 12.5%, p = 0.60). Conclusions Clinically relevant CAD is frequently associated with the presence of NAFLD, but not NAFLD with advanced fibrosis.

【 授权许可】

CC BY